(OTCBB: VYEY), (OTCBB: EFSF),(NASDAQ: SMMX).

Turning Pennies into dollars: (OTCBB: VYEY), (OTCBB: EFSF),(NASDAQ: SMMX).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://vyey.realpennies.com

Victory Energy Corporation (OTCBB: VYEY)(March 3, 2008) announced yesterday that a new drilling rig has been delivered to its drilling contractor for work in the Corporation's Canyon Sandstone Gas play located in Crockett County, Texas.

The contractor expects to have the rig completely tested and outfitted with the necessary auxiliary equipment by March 11, 2008. This new rig will be available for the next well the Corporation has targeted to drill.

Victory will register its petroleum holdings in the State of Texas, to correspond with its quarterly reports. Victory has a 15% Carried Interest of 74% Net Revenue Interest in each producing well the Corporation develops. Victory's interest increases to 25% Carried Interest of 74% Net Revenue Interest upon payback of the initial drilling investment costs of each well. The Corporation has established a financial facility with Institutional investors providing drilling funds to Victory for the further development of the Canyon Sandstone Gas field. This facility provides for direct participation by the investors in the production of the completed wells on a case-by-case basis.

"Victory will now have the option to have multiple wells being drilled and completed at the same time, this will increase the momentum the Corporation has already established in Crockett County, Texas," stated Jon Fullenkamp, President of Victory Energy Corporation.

About Victory Energy Corporation:

Victory Energy Corporation (http://www.victoryenergyoilandgas.com) is a publicly traded, developmental stage petroleum company primarily dedicated to energy-related opportunities. The Company goal is to evaluate profitable options, develop a solid foundation through leadership and sound business acumen, and acquire producing wells as well as other potentially profitable prospects within the Oil & Gas Industry.

For more info: http://efsf.realpennies.com

eFoodSafety.com, Inc. (OTCBB: EFSF)(March 3, 2008), through its wholly-owned subsidiary Knock-Out Technologies Ltd., announced yesterday they have developed and will begin clinical testing of Proxorin, based on the company's CitroxinTM formula, for use as a natural antibiotic/anti-microbial for treatment against a broad spectrum of common bacterial pathogens. Unlike many antibiotics, which often have a limited range of applications, Proxorin's natural composition allows it to be used in a range of conditions where anti-microbials are needed.

As an antibiotic, Proxorin can offer several advantages over common drug-based antibiotics. Its ability to confer its benefits against both gram-negative and gram-positive bacteria enables it to be used to treat a broad spectrum of bacterial pathogens. Proxorin also produces far fewer side effects than other common antibiotic pharmaceuticals, thereby reducing the likelihood of rebound infections. In addition, Proxorin can provide benefits to those patients who experience allergic reactions to a spectrum of "cillin" drugs. Finally, an enormous problem for the normal armament of antibiotics is the potential for "bugs" to develop resistance to the beneficent effects of a given antibiotic-a scenario that is highly unlikely to occur with Proxorin.

Initial microbial inhibition tests prove Proxorin extremely effective in eradicating MRSA, the methicillin resistant form of Staphylococcus aurous, and other studies of the formula show a 100% kill rate for common bacteria including: E. coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus. eFoodSafety expects to offer the antibiotic both as a high potency pill for oral ingestion and as a trans-dermal cream. These two forms utilize proprietary technology to offer controlled and targeted release of the active compounds to ensure maximum bio-availability and benefits.

"The decision to conduct clinical testing of Proxorin as a natural antibiotic is based on the encouraging microbial inhibition test results showing its ability to eradicate MRSA as other common bacterial pathogens," says Robert Bowker, President of Knock-Out Technologies. "These widespread bacterial pathogens are becoming increasingly difficult and expensive to defeat using conventional pharmaceutical methods. Importantly, eFoodSafety can offer Proxorin as both a high potency pill for oral ingestion and as a trans-dermal cream that provides effective absorption without having to go through normal digestion. We believe that with positive clinical results, our natural treatment can provide a superior solution to patients seeking treatment."

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte product, which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture, is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.

The Company is the owner of Cinnergen, a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism available for sale at (www.cinnergen.com) and through national retailers; and Cinnechol, a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect anti-acne skin care system.

The company's iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar, a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body's immune system. The product contains Citroxin, eFoodSafety's proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar is available in three delicious flavors: chocolate, oatmeal-raisin, and orange-apple and can be purchased at www.immuneboost.com.

The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn line.

For more info: http://smmx.realpennies.com

Symyx Technologies, Inc. (NASDAQ: SMMX)(March 3, 2008) announced yesterday that it has joined the Microsoft BioIT Alliance, a cross-industry group working to enhance collaboration among life sciences organizations to accelerate the pace of drug discovery and development.

"Comprehensive data integration -- making complex life sciences data easier to manage and easier to share -- requires new levels of cooperation between software companies," said Timothy Campbell, President of Symyx Software. "Symyx is delighted to be part of Microsoft's BioIT Alliance initiative. As a technology leader in integrated laboratory workflow systems, R&D software and research services in the life sciences and related industries, we look forward to working closely with Microsoft's partner community to explore new and better ways of capturing, managing and sharing R&D data. Through improved collaboration, multidisciplinary R&D organizations can solve critical life sciences problems more quickly and bring new products to market with less risk." Rudy Potenzone, Worldwide Industry Technology Strategist for Pharmaceuticals and BioIT Alliance Coordinator, said: "We are very pleased to welcome Symyx to the BioIT Alliance. Their broad experience and contribution to this community will help the Alliance and its members as we look to expand our activities in the coming months." The BioIT Alliance is designed to enable collaboration among organizations in the life sciences field in order to shorten the time between discovery of new biological data and the application of that knowledge to human health. Symyx will work with other alliance members to consider innovative ways to address the challenges of data integration, collaboration, and knowledge management and use Microsoft technology to reduce costs, streamline research and market products more effectively.

About Symyx

Symyx Technologies, Inc. is the scientific R&D integration partner to companies in the life sciences, chemicals, energy, electronics and consumer products industries. With scientific R&D under tremendous economic and technical pressure, we help companies reduce R&D risk and enhance R&D productivity to help them bring more and better products to market quickly and cost-effectively. Our integrated technology platform combines Symyx Software (electronic laboratory notebooks, content, laboratory logistics and analysis), Symyx Tools (software-driven integrated workflows) and Symyx Research (collaborative research and directed services) to support the entire R&D process. In October 2007, Symyx acquired MDL Information Systems, Inc., a leading provider of innovative informatics software, databases and services that accelerate successful scientific R&D by improving the speed and quality of scientists' decision making. Information about Symyx, including reports and other information filed by Symyx with the Securities and Exchange Commission, is available at www.symyx.com.

About BioIT Alliance

Formed in 2006, the BioIT Alliance is a cross-industry group working to integrate science and technology in order to accelerate the pace of drug discovery and realize the potential of personalized medicine. Founding members include Accelrys Software Inc., Affymetrix, Inc., Agilent Technologies Inc., Amylin Pharmaceuticals, Inc., Applied Biosystems, The BioTeam Inc., Digipede Technologies LLC, Discovery Biosciences Corporation, Geospiza Inc., Hewlett-Packard Development Company, L.P., Illumina Inc., InterKnowlogy, Microsoft Corporation, Sun Microsystems Inc., The Scripps Research Institute, VizX Labs LLC and other key companies in the pharmaceutical, biotech, hardware and software industries. Additional information about the BioIT Alliance can be found on the BioIT Alliance Web site at http://www.bioitalliance.org

About Microsoft

Founded in 1975, Microsoft (NASDAQ: MSFT) is the worldwide leader in software, services and solutions that help people and businesses realize their full potential. For more information, please visit www.microsoft.com Symyx is a registered trademark of Symyx Technologies, Inc. Microsoft is a registered trademark of the Microsoft Corporation in the United States and other countries. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com